July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Mixed Effects Models Indicate Several SNPs within the CNTNAP2 Gene Increase Rate of Glaucoma Related Visual Field Loss
Author Affiliations & Notes
  • Argus Athanas-Crannell
    University California San Diego, San Diego, California, United States
  • Mark Christopher
    Viterbi Family Department of Opthalmology, Shiley Eye Institue, La Jolla, California, United States
  • Yongwook Choi
    Human Biology, The J. Craig Venter Institute, La Jolla, California, United States
  • Agnes Chan
    Human Biology, The J. Craig Venter Institute, La Jolla, California, United States
  • Linda M Zangwill
    Viterbi Family Department of Opthalmology, Shiley Eye Institue, La Jolla, California, United States
  • Jeffrey M Liebmann
    Bernard and Shirlee Brown Glaucoma Research Laboratory, Harkness Eye Institute, Columbia, New York, New York, United States
  • Christopher A Girkin
    Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Robert M Feldman
    Ruiz Department of Ophthalmology, University of Texas Health Science Center, Houston, Texas, United States
  • Kent D Taylor
    Institute for Translational Genomics and Population Sciences, Torrance, California, United States
  • Jerome I Rotter
    Institute for Translational Genomics and Population Sciences, Torrance, California, United States
  • Harvey DuBiner
    Eye Care Center Management, Marrow, Georgia, United States
  • Radha Ayyagari
    Viterbi Family Department of Opthalmology, Shiley Eye Institue, La Jolla, California, United States
  • Nicholas Schork
    Viterbi Family Department of Opthalmology, Shiley Eye Institue, La Jolla, California, United States
    Department of Quantitative Medicine and Systems Biology, The Translational Genomics Research Institute, Phoenix, Arizona, United States
  • Robert N Weinreb
    Viterbi Family Department of Opthalmology, Shiley Eye Institue, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Argus Athanas-Crannell, None; Mark Christopher, None; Yongwook Choi, None; Agnes Chan, None; Linda Zangwill, Carl Zeiss Meditec Inc (F), Heidelberg Engineering (R), Heidelberg Engineering GmbH (F), National Eye Institute (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F); Jeffrey Liebmann, Alcon (C), Allergan Inc. (C), Bausch & Lomb (F), Bausch & Lomb, Inc. (C), Carl Zeiss Meditec (F), Carl Zeiss Meditech, Inc. (C), GmbH (C), Heidelberg Engineering (C), Heidelberg Engineering (F), National Eye Institute (F), Optovue (F), Reichert (C), Reichert (F), Topcon (F), Valeant Pharmaceuticals (C); Christopher Girkin, Carl Zeiss Meditec Inc. (F), GmbH (F), Heidelberg Engineering (F), Heidelberg Engineering (R), National Eye Institute (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F); Robert Feldman, None; Kent Taylor, None; Jerome Rotter, None; Harvey DuBiner, None; Radha Ayyagari, None; Nicholas Schork, None; Robert Weinreb, Aerie Pharmaceuticals (C), Alcon (C), Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec (F), Centervue (F), Eyenovia (C), Genentech (F), Heidelberg Engineering (F), Konan (F), Novartis (C), Optos (F), Optovue (F), Sensimed (C), Topcon (F), Unity (C), Valeant (C)
  • Footnotes
    Support  NLM T15 grant NIH/NLM T15LM011271, EY023704, P30EY022589, EY110008, EY021237, EY019869, EY026590, EY027510 EY021818; Dr. Schork and his lab are supported in part by NIH/NIA grants 2 U19 AG023122 and U24AG051129, NIH/NCATS grant UL1TR001442, as well as Johnson and Johnson, Inc. Unrestricted grant from Research to Prevent Blindness, New York, New York
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1620. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Argus Athanas-Crannell, Mark Christopher, Yongwook Choi, Agnes Chan, Linda M Zangwill, Jeffrey M Liebmann, Christopher A Girkin, Robert M Feldman, Kent D Taylor, Jerome I Rotter, Harvey DuBiner, Radha Ayyagari, Nicholas Schork, Robert N Weinreb; Mixed Effects Models Indicate Several SNPs within the CNTNAP2 Gene Increase Rate of Glaucoma Related Visual Field Loss. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1620. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Interrogate the CNTNAP2 gene’s contribution to rate of visual field loss in patients with glaucoma from individuals of African descent (AD) and European descent (ER).

Methods : Previous meta-GWAS analysis on 1,120 glaucoma patients in two different ancestries (ER: 557, AD: 563) highlighted the CNTNAP2 gene as potential contributor to the rate of visual field (VF) loss. This gene has already been associated with pseudoexfoliation syndrome, but not previously associated with glaucoma. Using whole-genome sequence data from these same individuals and clinical longitudinal covariates over a period of 2 – 19 years, mixed effects models (MEM) were used to supply additional evidence for the effect of SNPs within the CNTNAP2 gene. Models were built for suspected SNPs identified in the previous analyses, across 14 different visual field metrics. The power to detect signal is boosted by including time series data. MEM allow for within subject correlation between eyes, and adjustments for serial correlation. In addition to MEM, combined SNP effects were addressed using polygenic risk scores. Because most SNPs fell within the intergenic regions of the CNTNAP2 gene, potential effects were evaluated using various deleterious scoring metrics (CADD, PolyPhen2) and their predicted involvement in promotor and enhancer regions.

Results : Probabilistic comparison of the fit of MEM with and without SNP effect terms was used to determine the significance of each SNP on the rate of visual field loss. In the ER population of the 40 SNPs tested 38 were below P=5.5e-4. Six of these SNPs were previously identified enhancer / promotor regions for CNTNAP2. In the AD population only 9 of the 35 SNPs tested were statistically significant, and 2 of these 9 were within enhancer / promotor regions. Among the covariates included in the model, age, and sex were significant. IOP, medication, and procedures have yet to be included. These models were able to include 4.7 times as many data points for each SNP compared to previous GWAS analysis.

Conclusions : Previous analysis provided suggestive evidence that CNTNAP2 may play an influential role in the rate of decline of visual fields for patients with glaucoma. Our analysis provides additional support by including longitudinal modeling, a greater number of data points, important covariate effects, and greater biological annotation and evidence than previous studies.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×